

Supplementary Information

A small gene sequencing panel realises a high diagnostic rate in patients with congenital nystagmus following basic phenotyping

Luke O’Gorman, Chelsea S. Norman, Luke Michaels, Tutte Newall, Andrew H. Crosby, Christopher Mattocks, Angela J. Cree, Andrew J. Lotery, Emma L. Baple, J. Arjuna Ratnayaka, Diana Baralle, Helena Lee, Daniel Osborne, Fatima Shawkat, Jane Gibson, Sarah Ennis⁺, Jay E Self⁺*

¹Human Development and Health, Faculty of Medicine, University of Southampton, MP808, Tremona Road, Southampton SO16 6YD, UK

²Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, MP806, Tremona Road, Southampton, SO16 6YD, UK

³Eye Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, UK

⁴Institute of Biomedical and Clinical Science, University of Exeter Medical School, RILD Wellcome Wolfson Centre, Exeter, EX2 5DW, UK

⁵Wessex Investigational Science Hub, University Hospital Southampton, Tremona Road, Southampton SO16 6YD, UK

⁶Medical Research (Level 4), University of Exeter Medical School, RILD Wellcome Wolfson Centre, Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter, EX2 5DW, UK.

⁷Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, SO17 1BJ, UK

⁸Human Genetics & Genomic Medicine, Faculty of Medicine, University of Southampton, MP 808, Tremona Road, Southampton SO16 6YD, UK

*J.E.Self@soton.ac.uk

⁺Joint last authorship

Table S1 UKGTN gene panel for 'Nystagnus and albinism'. HGNC approved gene names for genes listed in the UKGTN gene panel for 'Nystagnus and albinism' with the associated OMIM inheritance pattern and phenotype.

Symbol (HGNC)	Loci (HGNC)	Assumed inheritance pattern (OMIM)	Phenotype (OMIM)	Median Coding Sequence coverage at 20X depth of the n=81 cohort (RefSeq Curated)
<i>AP3B1</i>	5q14.1	AR	Hermansky-Pudlak syndrome 2	0.992
<i>BLOC1S3</i>	19q13.32	AR	Hermansky-Pudlak syndrome 8	0.943
<i>BLOC1S6</i>	15q21.1	AR	Hermansky-Pudlak syndrome 9	0.836
<i>C10orf11</i>	10q22.2-q22.3	AR	Albinism, oculocutaneous, type VII	0.705
<i>CACNA1A</i>	19p13.13	AD	Episodic ataxia, type 2	0.934
<i>CACNA1F</i>	Xp11.23	XL	Aland Island eye disease	0.985
<i>CASK</i>	Xp11.4	XLD	FG syndrome 4	0.980
<i>DTNBP1</i>	6p22.3	AR	Hermansky-Pudlak syndrome 7	0.993
<i>FRMD7</i>	Xq26.2	XL	Nystagnus 1, congenital, X-linked	0.961
<i>GPR143</i>	Xp22.2	XL	Ocular albinism, type I	0.844
<i>HPS1</i>	10q24.2	AR	Hermansky-Pudlak syndrome 1	0.929
<i>HPS3</i>	3q24	AR	Hermansky-Pudlak syndrome 3	0.994
<i>HPS4</i>	22q12.1	AR	Hermansky-Pudlak syndrome 4	0.977
<i>HPS5</i>	11p15.1	AR	Hermansky-Pudlak syndrome 5	0.975
<i>HPS6</i>	10q24.32	AR	Hermansky-Pudlak syndrome 6	1.000
<i>LYST</i>	1q42.3	AR	Chediak-Higashi syndrome	0.969
<i>MANBA</i>	4q24	AR	Mannosidosis, beta	0.991
<i>MITF</i>	3p13	AR	Tietz albinism-deafness syndrome	0.980
<i>MLPH</i>	2q37.3	AR	Griscelli syndrome, type 3	0.992
<i>MYO5A</i>	15q21.2	AR	Griscelli syndrome, type 1	0.987
<i>OCA2</i>	15q12-q13.1	AR	Albinism, oculocutaneous, type II	0.991
<i>PAX6</i>	11p13	AD	Foveal hypoplasia 1	0.945
<i>RAB27A</i>	15q21.3	AR	Griscelli syndrome, type 2	0.994
<i>SACS</i>	13q12.12	AR	Spastic ataxia, Charlevoix-Saguenay type	0.999
<i>SETX</i>	9q34.13	AR	Spinocerebellar ataxia, autosomal recessive 1	0.993
<i>SLC24A5</i>	15q21.1	AR	Albinism, oculocutaneous, type VI	0.995
<i>SLC45A2</i>	5p13.2	-	Albinism, oculocutaneous, type IV	0.939
<i>TULP1</i>	6p21.31	AR	Leber congenital amaurosis 15	0.981
<i>TYR</i>	11q14.3	AR	Albinism, oculocutaneous, type I	0.960
<i>TYROBP</i>	19q13.12	AR	Nasu-Hakola disease	0.988
<i>TYRP1</i>	9p23	AR	Albinism, oculocutaneous, type III	0.954

Table S2 *Overall coverage and contamination metrics of 81 samples.*

No. samples	Mean depth (X)	Mean coverage at 20x (%)	Min coverage at 20x (%)	Max coverage at 20x (%)	Mean hets (%)	Min hets (%)	Max hets (%)
81	127	95.8	90.6	0.987	65.2	57.4	72.2

